Related

Cruise evacuees face 42-day quarantine to contain hantavirus spread
Corina Pons and Victoria Waldersee 11 May 2026



Top stories






More news













ESG & Sustainability
Empowering people to prosper: Inside Empact’s first sustainability report



Women with mutations in the BRCA1 or BRCA2 gene have a higher risk of getting breast and ovarian cancers. Medical treatments can reduce the risk sharply, so genetic testing is recommended for women whose personal or family history shows they may have these mutations. Genetic testing is not recommended for women at average risk because the harms of treatment outweigh the benefits.
Researchers sent surveys to 3200 doctors in the United States that asked about the services they would provide to women at annual exams, including how often they would refer women to genetic counselling or offer BRCA 1/2 testing. Scenarios in the survey varied the patients' characteristics, such as age, race, insurance status, and ovarian cancer risk.
A total of 1878 doctors answered the survey, with the following results:
Doctors need to be encouraged to offer genetic counselling and testing services to high-risk women and discouraged from offering them to average-risk women.